EP3693364A1 — Crystalline salts of a hemoglobin s allosteric modulator
Assigned to Sandoz AG · Expires 2020-08-12 · 6y expired
What this patent protects
The present invention relates to new crystalline forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (also referred to as "voxelotor"), in particular to crystalline salts of voxelotor with 1,5-naphthalenedisulfonic acid (also referred t…
USPTO Abstract
The present invention relates to new crystalline forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (also referred to as "voxelotor"), in particular to crystalline salts of voxelotor with 1,5-naphthalenedisulfonic acid (also referred to as "voxelotor napadisylate" salts) and methods for preparing same. The invention also refers to a pharmaceutical composition comprising the said voxelotor napadisylate salts and one or more pharmaceutically acceptable excipients. The pharmaceutical composition of the present invention can be used as a medicament for increasing oxygen affinity of hemoglobin S, in particular for the treatment of oxygen deficiency associated with stickle cell anemia.
Drugs covered by this patent
- Oxbryta (voxelotor) · Global Blood Theraps
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.